medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Abstract Background Negative symptoms in schizophrenia spectrum disorders (SSD) remain insufficiently treated and require novel therapeutic approaches. Oxytocin may improve negative symptoms, although its effects appear highly context-dependent according to the social salience hypothesis. We conducted a randomized, triple-blind, placebo-controlled pilot study combining intranasal oxytocin with...
Schizophrenia
April 30, 2026
Marco Zierhut, S. Koop, N. Bergmann et al.
This study investigates changes in stress parameters in individuals with schizophrenia spectrum disorders participating in mindfulness-based group therapy (MBGT). N = 45 participants were randomised to MBGT or Treatment as Usual over four weeks. Before and after each session, psychological and biological stress markers by self-rating scales and cortisol saliva samples were assessed in the...
JAMA Psychiatry
March 25, 2026
Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al.
3 citations
Importance: Few pharmacotherapies are approved for treatment-resistant depression, and many patients do not achieve remission following treatment with those therapies. Objective: To examine the efficacy and safety of single-day treatment with a synthetic formulation of inhaled mebufotenin (GH001) vs placebo in patients with treatment-resistant depression. Design, Setting, and Participants: This...
Schizophrenia Bulletin
November 16, 2024
Inge Hahne, Marco Zierhut, Niklas Bergmann et al.
3 citations
The efficacy of yoga as an adjunctive treatment for schizophrenia spectrum disorders (SSD) has garnered interest. While yoga may positively influence various symptom domains, further investigation is needed due to the limited number, quality, and generalizability of studies. This study assessed the feasibility and acceptability (primary outcome) of a yoga-based group intervention (YoGI)...
European Psychiatry
November 17, 2023
Kerem Böge, Inge Hahne, Niklas Bergmann et al.
Introduction The therapeutic effectiveness of mindfulness-based interventions (MBIs) has been shown for various mental disorders. However, for schizophrenia spectrum disorders (SSD), only a few trials have been conducted, mostly in outpatient settings. Objectives This study aimed to investigate feasibility, acceptability, and preliminary effectiveness of a four-week mindfulness-based group...
The International Journal of Neuropsychopharmacology
August 10, 2022
Anne Weigand, Matti Gärtner, Milan Scheidegger et al.
22 citations
BACKGROUND: Growing evidence underscores the utility of ketamine as an effective and rapid-acting treatment option for major depressive disorder (MDD). However, clinical outcomes vary between patients. Predicting successful response may enable personalized treatment decisions and increase clinical efficacy. METHODS: We here explored the potential of pregenual anterior cingulate cortex (pgACC)...
Frontiers in Psychology
September 3, 2021
Niklas Bergmann, Eric Hahn, Inge Hahne et al.
Background: Schizophrenia spectrum disorders (SSD) are frequently accompanied by comorbid depressive and anxiety symptoms, as well as impaired quality of life (QoL). A growing body of evidence has demonstrated the relevance of mindfulness for SSD in recent years. The study examined the association between mindfulness, depression, anxiety, and QoL.Materials and Methods: A total of 83...
Psychosomatic Medicine
May 5, 2021
Thorsten Barnhofer, Tim Jonas Reeß, Maria Fißler et al.
24 citations
OBJECTIVE: Mindfulness-based interventions (MBIs) have been found to be a promising approach for the treatment of recurrent courses of depression. However, little is known about their neural mechanisms. This functional magnetic resonance imaging study set out to investigate activation changes in corticolimbic regions during implicit emotion regulation. METHODS: Depressed patients with a...
American Journal of Psychiatry
May 21, 2019
Vanina Popova, Ella Daly, Madhukar H. Trivedi et al.
879 citations
OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active...
Pharmacopsychiatry
September 1, 2011
Simone Grimm, Milan Scheidegger, Anke Henning et al.
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties, thus providing a valuable research tool for the investigation of the neurobiology of major depressive disorder (MDD). Increasing evidence underscores the role of glutamate dependent neuroplasticity and glutamatergic neurotransmission and metabolism in the pathophysiology of MDD. This multimodal...